Benralizumab for eosinophilic granulomatosis with polyangiitis and subclinical cardiac involvement: A fertility-preserving case report
Authors:
- 29 June 2026
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10 (2)
Abstract
Cardiac involvement, which may remain clinically silent, is a major determinant of prognosis in eosinophilic granulomatosis with polyangiitis, and remission induction generally requires glucocorticoids (GCs) combined with cyclophosphamide or rituximab. In contrast, treatment selection may be challenging in women wishing to preserve fertility because cyclophosphamide carries a risk of gonadal toxicity. We report the case of a 40-year-old woman with a history of asthma, eosinophilic chronic rhinosinusitis, and eosinophilic otitis media who developed postpartum-onset eosinophilic granulomatosis with polyangiitis and presented with neurological and cutaneous manifestations. Elevated cardiac troponin I levels and newly developed electrocardiographic abnormalities suggested subclinical myocardial injury despite the absence of cardiac symptoms. Intravenous methylprednisolone pulse therapy was initiated immediately. Because cardiac troponin I levels showed no early decline after GC initiation, and GC monotherapy was considered potentially insufficient to control eosinophil-mediated myocardial injury, additional eosinophil-targeted therapy was selected after shared decision-making that balanced fertility preservation with the need for prompt disease control. Benralizumab was chosen because of its potent eosinophil-depleting effect. Peripheral eosinophils rapidly decreased to zero, troponin I normalised by Day 26, and GCs were successfully discontinued within 5 months. To our knowledge, this is the first report of benralizumab used as part of a fertility-preserving remission-induction strategy to avoid cyclophosphamide in a woman with eosinophilic granulomatosis with polyangiitis and cardiac involvement. This approach may represent an individualised therapeutic option for carefully selected patients in whom fertility preservation is an important treatment consideration.Keywords
This publication has 38 references indexed in Scilit:
- Asthma management in pregnancy and lactation: A review of current evidence and best practice recommendationsnpj Primary Care Respiratory Medicine, 2026
- Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?The Journal of Allergy and Clinical Immunology: In Practice, 2026
- The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With PolyangiitisArthritis & Rheumatology, 2025
- Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitisAnnals of the Rheumatic Diseases, 2025
- EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 updateAnnals of the Rheumatic Diseases, 2025
- Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis PatientsJACC: Case Reports, 2024
- 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With PolyangiitisArthritis & Rheumatology, 2022
- Recurrent cardiac arrest due to eosinophilia-related coronary vasospasm successfully treated by benralizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitisAllergology International, 2020
- Eosinophilic MyocarditisJACC, 2017